|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 |
网站主页 >> 化工产品目录 >> Remogliflozin etabonate>> 市场分析报告 |
Remogliflozin etabonate市场分析报告 |
|
Non-Alcoholic SteatoHepatitis (NASH): An Analysis of Disease Prevalence, Drugs in development, Regulatory guidelines and Market opportunity in Various Geographies Sales of Hepatitis C drugs crossed ~$10bn in 2014 proving that treatments for liver disease could become mega-blockbusters and Non-Alcoholic SteatoHepatitis (NASH) is expected to be equally lucrative. Improved diagnosis rate and change in treatment ... Anti-Diabetic Drugs Market - Forecasts from 2020 to 2025 ... 2019: - Glenmark Pharmaceuticals announced to launch Remogliflozin etabonate in India. This drug is used to treat ... Sodium-glucose transporter 2 inhibitors - Pipeline Insight, 2022 ... Tofogliflozin Enavogliflozin Janagliflozin Bexagliflozin HEC44616 Remogliflozin etabonate Licogliflozin YG 1699 LYN?045 JNJ ... Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Biliary ... |